Muriel Laine
Overview
Explore the profile of Muriel Laine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laine M, Greene M, Kurleto J, Bozek G, Leng T, Huggins R, et al.
Breast Cancer Res
. 2024 Jun;
26(1):95.
PMID: 38849889
Background: Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways. The...
2.
Porter B, Frerich C, Laine M, Clark A, Durdana I, Lee J, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835373
Estrogen receptor-positive (ER+) invasive lobular breast cancer (ILC) comprises about ~15% of breast cancer. ILC's unique genotypic (loss of wild type E-cadherin expression) and phenotypic (small individual round cancer cells...
3.
Keelan S, Ola M, Charmsaz S, Cocchiglia S, Ottaviani D, Hickey S, et al.
Cancer Commun (Lond)
. 2023 Jan;
43(5):615-619.
PMID: 36670046
No abstract available.
4.
Hosfield D, Weber S, Li N, Sauvage M, Joiner C, Hancock G, et al.
Elife
. 2022 May;
11.
PMID: 35575456
Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend estrogen receptor alpha (ERα)...
5.
Laine M, Fanning S, Chang Y, Green B, Greene M, Komm B, et al.
Breast Cancer Res
. 2021 May;
23(1):54.
PMID: 33980285
Background: Endocrine therapy remains the mainstay of treatment for estrogen receptor-positive (ER+) breast cancer. Constitutively active mutations in the ligand binding domain of ERα render tumors resistant to endocrine agents....
6.
Cocce K, Jasper J, Desautels T, Everett L, Wardell S, Westerling T, et al.
Cell Rep
. 2019 Oct;
29(4):889-903.e10.
PMID: 31644911
Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that...
7.
Fanning S, Jeselsohn R, Dharmarajan V, Mayne C, Karimi M, Buchwalter G, et al.
Elife
. 2018 Nov;
7.
PMID: 30489256
Acquired resistance to endocrine therapy remains a significant clinical burden for breast cancer patients. Somatic mutations in the (estrogen receptor alpha (ERα)) gene ligand-binding domain (LBD) represent a recognized mechanism...
8.
Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling
Singhal H, Greene M, Zarnke A, Laine M, Al Abosy R, Chang Y, et al.
Oncotarget
. 2018 Feb;
9(4):4282-4300.
PMID: 29435103
Major roadblocks to developing effective progesterone receptor (PR)-targeted therapies in breast cancer include the lack of highly-specific PR modulators, a poor understanding of the pro- or anti-tumorigenic networks for PR...
9.
Singhal H, Greene M, Tarulli G, Zarnke A, Bourgo R, Laine M, et al.
Sci Adv
. 2016 Jul;
2(6):e1501924.
PMID: 27386569
The functional role of progesterone receptor (PR) and its impact on estrogen signaling in breast cancer remain controversial. In primary ER(+) (estrogen receptor-positive)/PR(+) human tumors, we report that PR reprograms...
10.
Abot A, Fontaine C, Buscato M, Solinhac R, Flouriot G, Fabre A, et al.
EMBO Mol Med
. 2014 Sep;
6(10):1328-46.
PMID: 25214462
Estetrol (E4) is a natural estrogen with a long half-life produced only by the human fetal liver during pregnancy. The crystal structures of the estrogen receptor α (ERα) ligand-binding domain...